In this phase II , randomized , double-blind study , placebo or ixekizumab was administered subcutaneously to 260 biologics-naive patients and 188 patients with an inadequate response to TNF inhibitors at weeks 0 , 1 , 2 , 4 , 6 , 8 , and 10 with concomitant disease-modifying antirheumatic drugs .